Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D003864:Depression, Chemical; D004296:Dopa Decarboxylase / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D011339:Probenecid / Q000134:cerebrospinal fluid*; D013268:Stimulation, Chemical; D013997:Time Factors
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004338:Drug Combinations; D010648:Phenylacetates; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D004296:Dopa Decarboxylase; D011339:Probenecid; D006719:Homovanillic Acid